Last reviewed · How we verify

Cholinesterase Inhibitor

Sunnybrook Health Sciences Centre · Phase 3 active Small molecule

Cholinesterase Inhibitor is a Cholinesterase inhibitor Small molecule drug developed by Sunnybrook Health Sciences Centre. It is currently in Phase 3 development for Alzheimer's disease (cognitive decline), Myasthenia gravis. Also known as: Galantamine, Donepezil, Rivastigmine.

Cholinesterase inhibitors block the enzyme that breaks down acetylcholine, allowing acetylcholine to accumulate in the synapse and enhance cholinergic neurotransmission.

Cholinesterase inhibitors block the enzyme that breaks down acetylcholine, allowing acetylcholine to accumulate in the synapse and enhance cholinergic neurotransmission. Used for Alzheimer's disease (cognitive decline), Myasthenia gravis.

At a glance

Generic nameCholinesterase Inhibitor
Also known asGalantamine, Donepezil, Rivastigmine
SponsorSunnybrook Health Sciences Centre
Drug classCholinesterase inhibitor
TargetAcetylcholinesterase
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

These drugs inhibit acetylcholinesterase, the enzyme responsible for degrading acetylcholine at the neuromuscular junction and in the central nervous system. By preventing acetylcholine breakdown, the drugs increase acetylcholine concentration and duration of action at cholinergic receptors, enhancing neuromuscular and cognitive function. This mechanism is particularly useful in conditions characterized by cholinergic deficiency, such as Alzheimer's disease and myasthenia gravis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cholinesterase Inhibitor

What is Cholinesterase Inhibitor?

Cholinesterase Inhibitor is a Cholinesterase inhibitor drug developed by Sunnybrook Health Sciences Centre, indicated for Alzheimer's disease (cognitive decline), Myasthenia gravis.

How does Cholinesterase Inhibitor work?

Cholinesterase inhibitors block the enzyme that breaks down acetylcholine, allowing acetylcholine to accumulate in the synapse and enhance cholinergic neurotransmission.

What is Cholinesterase Inhibitor used for?

Cholinesterase Inhibitor is indicated for Alzheimer's disease (cognitive decline), Myasthenia gravis.

Who makes Cholinesterase Inhibitor?

Cholinesterase Inhibitor is developed by Sunnybrook Health Sciences Centre (see full Sunnybrook Health Sciences Centre pipeline at /company/sunnybrook-health-sciences-centre).

Is Cholinesterase Inhibitor also known as anything else?

Cholinesterase Inhibitor is also known as Galantamine, Donepezil, Rivastigmine.

What drug class is Cholinesterase Inhibitor in?

Cholinesterase Inhibitor belongs to the Cholinesterase inhibitor class. See all Cholinesterase inhibitor drugs at /class/cholinesterase-inhibitor.

What development phase is Cholinesterase Inhibitor in?

Cholinesterase Inhibitor is in Phase 3.

What are the side effects of Cholinesterase Inhibitor?

Common side effects of Cholinesterase Inhibitor include Nausea, Vomiting, Diarrhea, Muscle cramps, Bradycardia, Syncope.

What does Cholinesterase Inhibitor target?

Cholinesterase Inhibitor targets Acetylcholinesterase and is a Cholinesterase inhibitor.

Related